XOMA Royalty (XOMA) Asset Writedowns and Impairment (2012 - 2020)

XOMA Royalty (XOMA) reported Asset Writedowns and Impairment of -$1.4 million for Q4 2020, down 199.36% sequentially from $1.4 million in Q1 2020.

XOMA Royalty (XOMA) Asset Writedowns and Impairment (2012 - 2020) Analysis & Trends

XOMA Royalty (XOMA) has 2 years of Asset Writedowns and Impairment data on file, last reported at -$1.4 million in Q4 2020.

  • For the quarter ending Q4 2020, Asset Writedowns and Impairment changed N/A year-over-year to -$1.4 million; the trailing twelve-month figure through Dec 2020 stood at $9000.0 (changed N/A YoY), and the FY2023 full-year result was $14.3 million, changed N/A from the prior year.
  • Asset Writedowns and Impairment eased to -$1.4 million in Q4 2020, from $1.4 million in the prior quarter.
  • In the past five years, Asset Writedowns and Impairment ranged from a high of $1.4 million in Q1 2020 to a low of -$1.4 million in Q4 2020.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Oculis Holding AG 66,621.14 Bn 66,620.85 Bn -
2 Nanobiotix 1,915.18 Bn 1,915.11 Bn -
3 Akari Therapeutics 1,014.18 Bn 1,014.18 Bn -
4 BeOne Medicines 471.27 Bn 466.48 Bn 1.35 Bn
5 Vertex Pharmaceuticals 121.81 Bn 114.57 Bn 2.59 Bn
6 Regeneron Pharmaceuticals 69.58 Bn 60.82 Bn 3.31 Bn
7 Belite Bio 62.72 Bn 62.72 Bn -
8 Argenx Se 55.51 Bn 50.33 Bn 1.41 Bn
9 Revolution Medicines 37.35 Bn 37.35 Bn -
10 XOMA Royalty 478.42 Mn 412.34 Mn -

Historic Data

Download Data
DateValue
Dec 31, 2020 -1.40 Mn
Dec 31, 2020 -1.40 Mn
Mar 31, 2020 1.41 Mn
Mar 31, 2020 1.41 Mn
Dec 31, 2012 219,000.00
Dec 31, 2012 219,000.00
Sep 30, 2012 160,000.00
Sep 30, 2012 160,000.00
Jun 30, 2012 374,000.00
Jun 30, 2012 374,000.00
Mar 31, 2012 1.71 Mn
Mar 31, 2012 1.71 Mn